Dark spots and melasma: the creams the trials back, and what newer studies only hint at

Brown patches and dark spots on the face have several causes, and the honest starting point is that the best-studied kind — melasma — is hard to shift and prone to coming back. The Cochrane reviewers who examined the treatments put it bluntly: available treatments for melasma are unsatisfactory [s1]. That is not a reason to do nothing. It is a reason to be realistic about which products have randomised evidence behind them and which are riding on marketing.

What causes the spots

The two common patterns are melasma and post-inflammatory hyperpigmentation. Melasma is an acquired symmetrical pigmentary disorder in which confluent grey-brown patches typically appear on the face [s1]. It reflects overactive pigment cells, driven by sunlight and by hormones, which is why it is far more common in women and often appears in pregnancy or with the contraceptive pill. It comes in epidermal, dermal, and mixed types depending on how deep the pigment sits — and depth matters, because pigment lodged deeper in the skin is much harder to reach with a cream [s1]. Post-inflammatory hyperpigmentation is the flat brown mark left after acne, eczema or an injury heals, as inflammation switches on the same pigment machinery.

Because ultraviolet light drives all of it, daily broad-spectrum sun protection is not an optional extra. It is the foundation any treatment is built on, and without it the spots return.

What the strongest evidence backs

The most rigorous synthesis remains a Cochrane review of 20 studies with 2,125 participants, covering 23 different treatments [s1]. The trials were too different to pool into one number, so the findings are comparisons between specific products [s1].

The clearest winner was the triple-combination cream — hydroquinone, tretinoin and fluocinolone acetonide together. It was significantly more effective at lightening melasma than hydroquinone alone, with a risk ratio of 1.58 (95% confidence interval 1.26 to 1.97), and it beat the two-drug combination of tretinoin and hydroquinone with a risk ratio of 2.75 (1.59 to 4.74) [s1]. Against weaker two-drug pairings the gap was larger still — a risk ratio of 14.00 (4.43 to 44.25) versus tretinoin plus fluocinolone acetonide [s1]. The message is that the three-agent formula is the reference treatment, but it is a prescription product that carries its own irritation risk and is not meant for indefinite use.

Azelaic acid holds up as a gentler option. Azelaic acid 20% was significantly more effective than 2% hydroquinone, with a risk ratio of 1.25 (1.06 to 1.48) — but it was not clearly better than the stronger 4% hydroquinone, where the risk ratio of 1.11 (0.94 to 1.32) crossed the line of no effect [s1]. Tretinoin used alone helped too: in one trial participants rated their melasma as significantly improved against placebo, with a risk ratio of 13 (1.88 to 89.74), though a second trial did not show the same participant-rated benefit [s1]. Across the board the side effects were mild and transient — skin irritation, itching, burning and stinging [s1].

What the newer research suggests — with a caveat

Attention has since shifted to tranexamic acid and to procedures. A 2025 network meta-analysis pooled 14 clinical trials testing 15 treatment modalities in 738 women, restricted to trials run between January 2022 and January 2025 [s2]. It ranked intradermal platelet-rich plasma, alone and combined with oral tranexamic acid, as the best-performing options on the Melasma Area Severity Index, and rated the overall quality of evidence as generally high [s2]. The authors were candid that platelet-rich plasma is a direction for future treatments rather than a settled one, and that large, well-designed trials are still needed to confirm it [s2].

A separate 2025 systematic review focused on how much treatments improve quality of life, not just appearance. From 1,296 records it included 23 papers containing 34 studies, and found that oral treatment, topical treatment and chemical peeling all reduced both the Melasma Area Severity Index and scores on the Melasma Quality of Life scale [s3]. It also reported high heterogeneity and methodological limitations across the studies — the recurring theme in this field [s3].

The realistic takeaway

For everyday dark spots and melasma, the evidence supports a modest, layered plan: rigorous daily sun protection, a topical lightening agent such as azelaic acid or a hydroquinone-based cream under medical guidance, and, for stubborn cases, a supervised prescription combination or an in-clinic procedure. None of it is a permanent cure, relapse is common, and the flashier procedures rest on smaller and newer studies than their marketing implies.

See a doctor or dermatologist if a pigmented patch is changing, growing, has an irregular border or varied colour, itches or bleeds, or is a single new dark spot rather than a symmetrical pattern — those features can point to something other than benign pigmentation and need proper assessment rather than a lightening cream.

This article is informational and is not medical advice.

Sources

• [s1] Interventions for melasma — Cochrane Database of Systematic Reviews, 7 July 2010. https://doi.org/10.1002/14651858.CD003583.pub2
• [s2] Efficacy and Safety of Different Treatments for Melasma: Network Meta-Analysis of Updated Data — Diseases, 25 September 2025. https://doi.org/10.3390/diseases13100316
• [s3] Systematic Review and Meta-Analysis of Treatments on Melasma Area Severity Index and Quality of Life — Pharmaceutics, 16 December 2025. https://doi.org/10.3390/pharmaceutics17121619